SAN DIEGO, April 13, 2016 /PRNewswire/ -- OncoSec
Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company
developing DNA-based intratumoral cancer immunotherapies, will host
a webcast to provide an overview and panel discussion regarding new
clinical data that will be featured as an oral presentation at the
upcoming American Association of Cancer Research (AACR) Annual
Meeting. The webcast will be held on Wednesday, April 20, 2016 at 11:00 AM ET/8:00 AM
PT.
The webcast will include a round table discussion to enable key
opinion leaders in the fields of melanoma and immuno-oncology to
contribute their respective insights on data from the AACR abstract
entitled: "Intratumoral electroporation of plasmid IL-12 can prime
response to anti-PD1/PD-L1 blockade in patients with Stage
III/IV-M1a melanoma" (Abstract #CT134). Webcast participants will
include:
- Alain Algazi, MD, Skin Cancer
Specialist, Melanoma Center, University of
California, San Francisco (UCSF) Helen Diller Family
Comprehensive Cancer Center
- Adil Daud, MD, Clinical
Professor, Department of Medicine (Hematology/Oncology), UCSF;
Director, Melanoma Clinical Research, UCSF Helen Diller Family
Comprehensive Cancer Center
- Robert Andtbacka, MD, CM,
Associate Professor, Division of Surgical Oncology, Department of
Surgery, University of Utah School of
Medicine; Surgeon and Investigator, Intermountain Healthcare and Huntsman Cancer
Institute
- Sharron Gargosky, PhD, Head of Clinical Development and
Operations, OncoSec*
- Moderator: Robert Pierce, MD,
Chief Scientific Officer, OncoSec
To join via webcast, please use the following link:
http://edge.media-server.com/m/p/np97wpek. To listen to the
conference call, please dial (877) 731-1960 and enter conference ID
number: 84899794. An archived version of the presentation will be
available for 90 days on the "Investors" section of OncoSec's
website: ir.oncosec.com/events.
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies for the treatment of cancer. The Company's
investigational technology, ImmunoPulse™, is designed to enhance
the local delivery and uptake of DNA-based immune-targeting agents,
such as interleukin-12 (IL-12). In Phase I and II clinical trials,
OncoSec's lead program, ImmunoPulse™ IL-12, demonstrated a
favorable safety profile and evidence of anti-tumor activity in the
treatment of various skin cancers as well as the potential to
initiate a systemic immune response. ImmunoPulse™ IL-12 is
currently in clinical development for several indications,
including metastatic melanoma and triple-negative breast cancer. In
addition to ImmunoPulse™ IL-12, the Company is also seeking to
identify and develop new immune-targeting agents for use with the
ImmunoPulse™ platform. For more information, please visit
www.oncosec.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by words such as
"will," "can," and similar references to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based on
management's current preliminary expectations and are subject to
risks and uncertainties, which may cause our results to differ
materially and adversely from the statements contained herein.
Potential risks and uncertainties that could cause actual results
to differ from those predicted include, among others, the
following: uncertainties inherent in pre-clinical studies and
clinical trials, such as the ability to enroll patients in clinical
trials and the risk of adverse events; unexpected new data,
safety and technical issues; our ability to raise additional
funding necessary to fund continued operations; and the other
factors discussed in OncoSec's filings with the Securities and
Exchange Commission.
Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
disclaims any obligation to update any forward-looking statements
to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events.
*Dr. Gargosky is serving as a consultant.
Contact
Mary
Marolla
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-to-host-webcast-and-panel-discussion-on-new-melanoma-clinical-data-300250654.html
SOURCE OncoSec Medical Incorporated